Abstract
Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Current Pharmaceutical Design
Title:Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond
Volume: 22 Issue: 42
Author(s): Amine Benyamina, Laurent Karila, Geneviève Lafaye and Lisa Blecha
Affiliation:
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Abstract: Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Export Options
About this article
Cite this article as:
Benyamina Amine, Karila Laurent, Lafaye Geneviève and Blecha Lisa, Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond, Current Pharmaceutical Design 2016; 22 (42) . https://dx.doi.org/10.2174/1381612822666160831095707
DOI https://dx.doi.org/10.2174/1381612822666160831095707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design The Role of Nuclear Receptor PPARα in the Sleep-wake Cycle Modulation. A Tentative Approach for Treatment of Sleep Disorders
Current Drug Delivery Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Editorial [Hot Topic: Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part II (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets A Rescue Factor for Alzheimers Diseases: Discovery, Activity, Structure,and Mechanism
Current Medicinal Chemistry Changing the Endocrine Dependence of Breast Cancer: Data and Hypotheses
Current Medicinal Chemistry Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Editorial [Hot topic: Models and Evolution of Inflammatory Activities (Executive Editor: Giuseppe Scapigliati)]
Current Pharmaceutical Design Recognition of Nucleic Acid Ligands by Toll-Like Receptors 7/8: Importance of Chemical Modification
Current Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Alpha-Secretase As a Therapeutic Target
Current Alzheimer Research Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
Current Neuropharmacology Acknowledgement To Reviewers
Current Neuropharmacology Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry